7
Participants
Start Date
March 19, 2014
Primary Completion Date
December 17, 2014
Study Completion Date
February 9, 2016
IXAZOMIB
"Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
Cleveland
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY